Physician
Internal Medicine
Dr. Brian P. Sorrentino, MD
|
|
Give Review
Brian Sorrentino works in the field of Internal Medicine. He attended State University of New York Upstate Medical University. He has 1 awards "Elected Member". Brian Sorrentino is also published. He has 98 publications published. The lastest publication: "Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.'
Publications
- Evaluating the safety of retroviral vectors based on insertional oncogene activation and blocked differentiation in cultured thymocytes.
- Abcg2 labeled cells contribute to different cell populations in the embryonic and adult heart.
- Gene therapy studies in a canine model of x-linked severe combined immunodeficiency.
- qsLAM PCR, an improved method for quantifying lentiviral vector insertion sites in transplanted hematopoietic cell systems.
- Charting a Clear Path: The ASGCT Standardized Pathways Conference.
- Interleukin-7 receptor mutants initiate early T cell precursor leukemia in murine thymocyte progenitors with multipotent potential.
- False-Positive HIV PCR Test Following Ex Vivo Lentiviral Gene Transfer Treatment of X-linked Severe Combined Immunodeficiency Vector.
- Drug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.
- Gene Therapy for Rare Diseases: Summary of a National Institutes of Health Workshop, September 13, 2012.
- Chemoprotection in brain tumor patients: another success for stem cell gene therapy.
- Abcg2 Expression Marks Tissue-Specific Stem Cells in Multiple Organs in a Mouse Progeny Tracking Model.
- Abcg2 labels multiple cell types in skeletal muscle and participates in muscle regeneration.
- Identification of a novel, tissue-specific ABCG2 promoter expressed in pediatric acute megakaryoblastic leukemia.
- Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies.
- A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.
- Hemgn is a direct transcriptional target of HOXB4 and induces expansion of murine myeloid progenitor cells.
- Scl and stem cell quiescence.
- In vivo selection of hematopoietic progenitor cells and temozolomide dose intensification in rhesus macaques through lentiviral transduction with a drug resistance gene.
- Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection.
- Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells.
- Interaction with the 5D3 monoclonal antibody is regulated by intramolecular rearrangements but not by covalent dimer formation of the human ABCG2 multidrug transporter.
- Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials.
- Expression of mouse Abcg2 mRNA during hematopoiesis is regulated by alternative use of multiple leader exons and promoters.
- Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy.
- Prospective isolation of murine hematopoietic stem cells by expression of an Abcg2/GFP allele.
- Genotoxicity of retroviral integration in hematopoietic cells.
- Acute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.
- A limited role for p16Ink4a and p19Arf in the loss of hematopoietic stem cells during proliferative stress.
- Increased expression of the Abcg2 transporter during erythroid maturation plays a role in decreasing cellular protoporphyrin IX levels.
- Function-dependent conformational changes of the ABCG2 multidrug transporter modify its interaction with a monoclonal antibody on the cell surface.
- The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme.
- Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem c...
- Hematopoietic cells from mice that are deficient in both Bcrp1/Abcg2 and Mdr1a/1b develop normally but are sensitized to mitoxantrone.
- Reduction in hematopoietic stem cell numbers with in vivo drug selection can be partially abrogated by HOXB4 gene expression.
- Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
- Development of gene therapy for hemoglobin disorders.
- Low levels of ABCG2 expression in adult AML blast samples.
- Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in v...
- Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5.
- Mouse Transplant Models for Evaluating the Oncogenic Risk of a Self-Inactivating XSCID Lentiviral Vector.
- Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resista...
- Vectors in cancer therapy: how will they deliver?
- Pilot study of high dose ICE (ifosfamide, carboplatin, etoposide) chemotherapy and autologous bone marrow transplant (ABMT) with neoR-transduced bone marrow and periph...
- Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy.
- Gene transfer into hematopoietic cells. Implications for cancer therapy.
- A 46 base pair enhancer sequence within the locus activating region is required for induced expression of the gamma-globin gene during erythroid differentiation.
- The imposter phenomenon in the clinical nurse specialist role.
- European School of Oncology position paper. Gene therapy for the medical oncologist.
- The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype.
- Fibronectin fragment CH-296 inhibits apoptosis and enhances ex vivo gene transfer by murine retrovirus and human lentivirus vectors independent of viral tropism in non...
- The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells.
- Protection and in vivo selection of hematopoietic stem cells using temozolomide, O6-benzylguanine, and an alkyltransferase-expressing retroviral vector.
- Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation.
- Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells.
- Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo.
- Inactivation of aldophosphamide by human aldehyde dehydrogenase isozyme 3.
- Retroviral transfer of the hENT2 nucleoside transporter cDNA confers broad-spectrum antifolate resistance in murine bone marrow cells.
- High levels of lymphoid expression of enhanced green fluorescent protein in nonhuman primates transplanted with cytokine-mobilized peripheral blood CD34(+) cells.
- Pluripotent hematopoietic stem cells contain high levels of mRNA for c-kit, GATA-2, p45 NF-E2, and c-myb and low levels or no mRNA for c-fms and the receptors for gran...
- Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherap...
- Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1.
- Localization and characterization of the DNase I-hypersensitive site II (HS II) enhancer. A critical regulatory element within the beta-globin locus-activating region.
- Inducibility of the HS II enhancer depends on binding of an erythroid specific nuclear protein.
- Tandem AP-1-binding sites within the human beta-globin dominant control region function as an inducible enhancer in erythroid cells.
- Effects of retroviral-mediated MDR1 expression on hematopoietic stem cell self-renewal and differentiation in culture.
- Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.
- Retroviral transfer of a bacterial alkyltransferase gene into murine bone marrow protects against chloroethylnitrosourea cytotoxicity.
- Use of the green fluorescent protein as a marker to identify and track genetically modified hematopoietic cells.
- In vivo selection of retrovirally transduced hematopoietic stem cells.
- Transduction of murine bone marrow cells with an MDR1 vector enables ex vivo stem cell expansion, but these expanded grafts cause a myeloproliferative syndrome in tran...
- Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase.
- In vitro mutations in dihydrofolate reductase that confer resistance to methotrexate: potential for clinical application.
- Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer.
- Comparison of the protection of cells from antifolates by transduced human dihydrofolate reductase mutants.
- A bicistronic retroviral vector for protecting hematopoietic cells against antifolates and P-glycoprotein effluxed drugs.
- Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors.
- Coding region-specific destabilization of mRNA transcripts attenuates expression from retroviral vectors containing class 1 aldehyde dehydrogenase cDNAs.
- Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro...
- Gene therapy in pediatric oncology.
- Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate.
- A gene transfer strategy for making bone marrow cells resistant to trimetrexate.
- Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic r...
- Gene transfer into human hemopoietic progenitor cells.
- Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice.
- In vivo selection of hematopoietic stem cells transduced with DHFR-expressing retroviral vectors.
- Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs.
- American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells.
- Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leuk...
- Clinical strategies for expansion of haematopoietic stem cells.
- Restoration of tolerance in lupus by targeted inhibitory receptor expression.
- Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
- Isolation, molecular cloning and in vitro expression of rhesus monkey (Macaca mulatta) prominin-1.s1 complementary DNA encoding a potential hematopoietic stem cell ant...
- Gene therapy: X-SCID transgene leukaemogenicity.
- Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia.
- Assessing the risk of T-cell malignancies in mouse models of SCID-X1.
- Antibody binding shift assay for rapid screening of drug interactions with the human ABCG2 multidrug transporter.
- The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation.
Schools
SUNY UPSTATE MED UNIV
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
- Internal Medicine
Accepted Insurances
Awards
- Elected Member
Education
-
State University of New York Upstate Medical University
Drug Facts
| NPI NUMBER | 1467501270 | |
| NPPES Provider LastName | SORRENTINO | |
| NPPES Provider FirstName | BRIAN | |
| NPPES Provider ZIPCode | 907203338 | |
| NPPES Provider State | CA | |
| Specialty Description | Physician Assistant | |
| Total Claim Count | 523.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467501270 |
| Last Name Of The Provider | SORRENTINO |
| First Name Of The Provider | BRIAN |
| View All |
Similar Doctors
|
Dr. James O. Patterson III, MD |
|
|
Dr. Paul J. Katz, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Todd V. Robinson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William K. Walsh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martha H. Sanford, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Baker L. Stewart, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amna G. Khattak, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Paul A. Ney, MD |
|
|
Dr. Mihaela Onciu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ibrahim Qaddoumi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dario Campana, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew E. Fintel, DO |
|
|
Dr. William H. West, MD |
|
|
Dr. Eric R. Wiedower, DO |
|
|
Dr. Robert W. Bradsher III, MD |
|
Dr. Jarvis D. Reed, MD
This Doctor is OpenDoctor Recommended.
|